This study analyzed the clinicopathological features and molecular changes in a cohort of 176 patients diagnosed with NSCLC, focusing on EGFR mutations, PD-L1 expression, and their associations with patient outcomes. This evidence concerns the gene EGFR and non-small cell lung carcinoma.